STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...

In efforts to better understand how plant photosynthesis is regulated, scientists are studying how Rubisco activity responds ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

In efforts to better understand how plant photosynthesis is regulated, scientists are studying how Rubisco activity responds to light. In a new meta-analysis study, a team from the Realizing Increased ...

A study published in the Journal of Bioresources and Bioproducts establishes quantitative structure-activity relationships governing surfactant efficacy against phenolic inhibition in lignocellulose ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born ...

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations.

Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians, has published results from the Phase 3 ENHANCE-CHINA trial evaluating ...

Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New ...